C
C4 Therapeutics, Inc. (CCCC)
NMS – Real Time Price. Currency in USD
3.17
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
3.12
-0.05 (-1.67%)
Pre-market: May 13, 2026, 4:55 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
3.17
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
3.12
-0.05 (-1.67%)
Pre-market: May 13, 2026, 4:55 AM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.81 | 6.05 | 10 | |
| Quick ratio | 7.81 | 5.63 | 10 | |
| Debt to Equity | 0.23 | 0.30 | 8.0 | |
| Debt to Assets | 0.16 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 31M | 21M | 36M | 36M | 36M |
| Gross Profit | 24M | 13M | 28M | 28M | 28M |
| Operating Income | -130M | -139M | -117M | -104M | -104M |
| Net Income | -128M | -132M | -105M | -105M | -105M |
| EBITDA | -122M | -131M | -109M | -97M | -97M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -38.66 | 32.26 | 5.5 |
| Next quarter | 19.4 | 33.14 | 9.5 |
| Current year | -39.87 | 14.32 | 4.5 |
| Next year | -11.57 | 8.01 | 3.5 |
| Weighted average score | 5.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -1.9 | 36.31 | 59.09 | 29.93 | 7.8 |
| Y/Y | 112.79 | 40.75 | 63.27 | -23.57 | 7.8 |
| 3y average | 13.07 | 5.82 | 19.21 | -3.18 | 5.8 |
| 5y average | 9.02 | -12.35 | 16.49 | -13.15 | 4.3 |
| Weighted average score | 6.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $74.6M significantly exceed its total debt $60.0M, ensuring strong financial flexibility
Total current assets $258.1M exceed Total current liabilities $33.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$22.2M limits the company's ability to reinvest or pay down debt